Similarly, ACM derived from OGJ patients with early-stage tumours had increased levels of other pro-inflammatory cytokines: IL-1RA, IL5 and IL-17A compared with ACM derived from OGJ patients with late-stage tumours (IL-1RA- early-stage: 29,939 ± 13,234 vs. late-stage: 7,312 ± 1,452 pg/gram p = 0.08, IL-5- early-stage: 3.68 ± 13.98 vs. late-stage: 7.20 ± 2.5 pg/gram p = 0.06, IL-17A- early-stage: 62.00 ± 10.81 vs. late-stage: 40.61 ± 8.5 pg/gram p = 0.08) (Figure S1B–D). This evidence concerns the gene IL17A and neoplasm.